201. D-TRP-6-LHRH (Triptorelin) is not effective in ovarian carcinoma: an EORTC gynaecological cancer co-operative group study
- Author
-
UCL - Autre, Duffaud, F, van der Burg, MEL, Namer, M, Vergote, Ignace, Willemse, PHB, Huinink, WT., Guastalla, JP., Nooij, MA, Kerbrat, P, Piccart, Martine, Tumolo, Salvatore, Favalli, G, van der Vange, N, Lacave, AJ., Wils, J., Splinter, TAW., Einhorn, N, Roozendaal, KJ, Rosso, R, Vermorken, JB., UCL - Autre, Duffaud, F, van der Burg, MEL, Namer, M, Vergote, Ignace, Willemse, PHB, Huinink, WT., Guastalla, JP., Nooij, MA, Kerbrat, P, Piccart, Martine, Tumolo, Salvatore, Favalli, G, van der Vange, N, Lacave, AJ., Wils, J., Splinter, TAW., Einhorn, N, Roozendaal, KJ, Rosso, R, and Vermorken, JB.
- Abstract
Between March and September 1988, 74 patients with progressive ovarian cancer after prior platinum-based therapy were treated with the luteinizing hormone-releasing hormone (LHRH) agonist Triptorelin (Decapeptyl(R)). Treatment consisted of i.m. injection of 3.75 mg of microencapsulated Triptorelin on days 1, 8 and 28 followed by 4-weekly injections until tumor progression. No objective responses were observed. Eleven out of 68 evaluable patients (16%) had stable disease. The median progression-free survival was 5 months in patients with disease stabilization and 2 months for all evaluable patients. The median survival for patients with disease stabilization was 17 months, whereas for all patients it was 4 months. The treatment was well tolerated; the only reported adverse events were incidental hot flushes. This study showed that the LHRH agonist Triptorelin has only modest efficacy in patients pretreated with platinum-containing chemotherapy. [(C) 2001 Lippincott Williams & Wilkins.].
- Published
- 2001